Supplementation of Dihomo-γ-Linolenic Acid for Pollen-Induced Allergic Symptoms in Healthy Subjects: A Randomized, Double-Blinded, Placebo-Controlled Trial.
Dihomo-γ-linolenic acid (DGLA) is an n-6 polyunsaturated fatty acid that has been shown to have anti-inflammatory and anti-allergic effects in mice and cell study. To date, however, no human intervention study has examined the effects of DGLA. Therefore, we investigated the effects of DGLA on pollen...
| Publicado en: | Nutrients Vol. 15; no. 15; pp. 3465 - 3481 |
|---|---|
| Autores principales: | , , |
| Formato: | research tables/charts randomized controlled trial Journal Article |
| Publicado: |
MDPI
Aug2023
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=169927589&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 169927589 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 20726643 B0TT jtl: Nutrients issn: 20726643 maglogo: N pubinfo: dt: Aug2023 vid: 15 iid: 15 pid: 97109 pub: MDPI artinfo: ui: 169927589 169927589 169927589 10.3390/nu15153465 169927589 ppf: 3465 ppct: 16 formats: tig: atl: Supplementation of Dihomo-γ-Linolenic Acid for Pollen-Induced Allergic Symptoms in Healthy Subjects: A Randomized, Double-Blinded, Placebo-Controlled Trial. aug: au: Yokoi, Kaori Yanagimoto, Kenichi Hayamizu, Kohsuke affil: Food Function R&D Center, Nissui Corporation, Tokyo 192-0919, Japan sug: subj: Pollen Adverse Effects Rhinitis, Allergic, Seasonal Drug Therapy Eye Diseases Drug Therapy Hypersensitivity Drug Therapy Linolenic Acids Therapeutic Use Drug Efficacy Dietary Supplementation Human Randomized Controlled Trials Funding Source Double-Blind Studies Descriptive Statistics Data Analysis Software Comparative Studies Japan Male Female Questionnaires Chi Square Test T-Tests Adult Middle Age Adult: 19-44 years Middle Aged: 45-64 years Male Female ab: Dihomo-γ-linolenic acid (DGLA) is an n-6 polyunsaturated fatty acid that has been shown to have anti-inflammatory and anti-allergic effects in mice and cell study. To date, however, no human intervention study has examined the effects of DGLA. Therefore, we investigated the effects of DGLA on pollen-induced allergic symptoms in healthy adults. We performed a randomized, double-blind, placebo-controlled, parallel-group study comprising healthy Japanese men and women. Each subject received four 250 mg capsules providing 314 mg DGLA/day (DGLA group, n = 18) or olive oil (placebo group, n = 15) for 15 weeks. The primary outcomes, classification of the severity of allergic rhinitis symptoms (CSARS), and the Japanese Rhino-conjunctivitis Quality of Life Questionnaire (JRQLQ) served as symptom scores during the pollen season. In the DGLA group, the cedar pollen associated symptoms of sneezing and a blocked nose in the CSARS were significantly lower than those in the placebo group (p < 0.05, p < 0.01, respectively). Significant trends were observed the symptoms of runny nose in the CSARS and total symptom score (TSS) in the JRQLQ for cedar pollen (p < 0.1). To our knowledge, this is the first study to report the effects of DGLA in humans, and the results suggest that DGLA is effective in reducing allergic symptoms caused by pollen. pubtype: Academic Journal doctype: research tables/charts randomized controlled trial Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|